Efficacy and safety of risankizumab, an interleukin-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis: 16-week results from the phase III IMMhance trial Meeting Abstract

sustainable development goals

publication date

  • November 1, 2017

webpage

published in

start page

  • E248

end page

  • E248

volume

  • 177

issue

  • 5